Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference
11 nov. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
10 nov. 2020 16h05 HE
|
Clearside Biomedical, Inc.
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2 Trials Using SCS Microinjector® Ongoing...
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020
30 oct. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina
23 sept. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery
11 sept. 2020 08h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe
26 août 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update
10 août 2020 16h05 HE
|
Clearside Biomedical, Inc.
- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs -- Engaged New Contract Manufacturer for...
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
10 août 2020 16h02 HE
|
Clearside Biomedical, Inc.
- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
04 août 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020
30 juil. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...